NCT02555709已完成1 期
A Randomized, Double-Blind, Placebo-Controlled Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Psoriatic Patients and Clinical Proof-of-Concept in Psoriatic Patients
Vitae Pharmaceuticals Inc., an Allergan affiliate14 个研究点 分布在 1 个国家目标入组 74 人开始时间: 2015年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 74
- 试验地点
- 14
- 主要终点
- safety data, including AEs, laboratory evaluations, ECG results, and vital signs assessments, will be listed by subject and summarized by dose and time point
研究概览
简要总结
This is a two-part, randomized, double-blind, placebo-controlled study in which VTP-43742 will be administered to normal healthy volunteers (NHV) and to moderate to severe psoriatic patients, both in sequential ascending dose panels.
详细描述
This is a prospective, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics effects of VTP-43742 in healthy volunteers conducted at a single, study center and in patients with moderate to severe chronic plaque-type psoriasis at approximately 8 study centers in the United States. A total of 108 participants will be enrolled in the study (48 healthy subjects and 60 psoriatic patients).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy males or females, 18 to 45 years of age, inclusive.
- •Body weight of at least 55 kg and body mass index of 18-32 kg/m2, inclusive.
- •Medically healthy with clinically insignificant screening results.
- •Women of child-bearing potential (WOCBP) may be enrolled if they agree to use two of the reliable forms of contraception
- •Men with partners who are WOCBP must agree that they and/or their partner will use two of the reliable forms of contraception
- •WOCBP must have a negative serum βhCG pregnancy test at the Check-in visit.
- •Voluntarily consent to participate in the trial
- •Psoriasis Patient Inclusion Criteria:
- •Confirmed diagnosis of chronic plaque-type psoriasis, diagnosed at least 6 months before study with at least moderate severity, which is defined as PASI≥10, PGA≥3, and % BSA≥8
- •Otherwise medically healthy and with otherwise clinically insignificant screening laboratory test results
- •Males or females, 18 to 75 years of age, inclusive
- •Body weight of at least 55 kg and body mass index of 18-35 kg/m2, inclusive.
- •WOCBP may be enrolled if they agree to use two of the reliable forms of contraception
- •Men with partners who are WOCBP must agree that they and/or their partner will use two of the reliable forms of contraception
- •WOCBP must have a negative serum β hCG pregnancy test at the Screening and Baseline visit
- •Voluntarily consent to participate in the trial
- •Healthy Volunteer
排除标准
- •Unwilling or unable to provide written informed consent
- •History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, coagulation, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
- •Evidence of organ dysfunction or any clinically significant deviation from normal in vital signs, physical examination, clinical laboratory determinations or ECG
- •Any major surgery within 3 months of Screening
- •Positive urine drug/alcohol testing at Screening or Baseline visit
- •Use of tobacco and/or nicotine-containing products within 3 months prior to the start of dosing of the trial
- •Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV Ab) at Screening
- •History or presence of alcoholism or drug abuse as defined in DSM V, Diagnostic Criteria for Drug and Alcohol Abuse
- •History of hypersensitivity or idiosyncratic reaction to drugs from multiple drug classes
- •Any previous gastrointestinal surgery or recent (within 3 months) history of gastrointestinal disease that could impact the absorption of the study drug
- •Blood donation or significant blood loss within 8 weeks prior to Day 1of the trial
- •Plasma donation within 7 days prior to Day 1 of the trial
- •Blood transfusion within 4 weeks of Screening
- •Positive serum pregnancy test (WOCBP) at the Screening or Baseline visit
- •Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical disease (e.g., infectious disease) must not be enrolled into this study
- •Any other medical, psychiatric, and /or social reason as determined by the Investigator
- •Psoriatic Patient Exclusion Criteria:
- •Unwilling or unable to provide written informed consent
- •Efficacy failure on two or more biological agents for the treatment of psoriasis when the failures occurred within one year of the initiation of the therapy of the first biological agent
- •Current treatment or history of treatment for psoriasis with biologicals within 6 months of study Day 1
- •Current treatment or history of treatment for psoriasis with non-biological systemic medications within 4 weeks of Day 1 and treatment with topical agents within 2 weeks of Day 1
- •History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, coagulation, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
- •Evidence of organ dysfunction or any clinically significant deviation from normal in vital signs, physical examination, clinical laboratory determinations or ECG
- •Any major surgery within 3 months of Screening
- •Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV Ab) at Screening
- •History or presence of alcoholism or drug abuse as defined in DSM IV, Diagnostic Criteria for Drug and Alcohol Abuse
- •History of hypersensitivity or idiosyncratic reaction to drugs from multiple drug classes
- •Any previous gastrointestinal surgery or recent (within 3 months) history of gastrointestinal disease that could impact the absorption of the study drug
- •Blood donation or significant blood loss within 8 weeks prior to Day 1 of the trial
- •Plasma donation within 7 days prior to Day 1 of the trial
- •Blood transfusion within 4 weeks of Screening
- •Positive serum pregnancy test (WOCBP) at the Screening or positive urine pregnancy test with confirmatory serum pregnancy test on Day 1
- •Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical disease (e.g., infectious disease) must not be enrolled into this study.
- •Any other medical, psychiatric, and /or social reason as determined by the Investigator
研究组 & 干预措施
VTP-43742 Dose 4
Experimental
healthy volunteers
干预措施: VTP-43742 (Drug)
Placebo 1
Placebo Comparator
healthy volunteers
干预措施: Placebo 1 (Drug)
VTP-43742 Dose 1
Experimental
healthy volunteers
干预措施: VTP-43742 (Drug)
VTP-43742 Dose 2
Experimental
healthy volunteers
干预措施: VTP-43742 (Drug)
VTP-43742 Dose 3
Experimental
healthy volunteers
干预措施: VTP-43742 (Drug)
VTP-43742 Dose 5
Experimental
healthy volunteers
干预措施: VTP-43742 (Drug)
VTP-43742 Dose 6
Experimental
healthy volunteers
干预措施: VTP-43742 (Drug)
VTP-43742 Dose 7
Experimental
healthy volunteers
干预措施: VTP-43742 (Drug)
Placebo 2
Placebo Comparator
psoriatic patients
干预措施: Placebo 2 (Drug)
VTP-43742 Dose 8
Experimental
psoriatic patients
干预措施: VTP-43742 (Drug)
VTP-43742 Dose 9
Experimental
psoriatic patients
干预措施: VTP-43742 (Drug)
VTP-43742 Dose 10
Experimental
psoriatic patients
干预措施: VTP-43742 (Drug)
VTP-43742 Dose 11
Experimental
psoriatic patients
干预措施: VTP-43742 (Drug)
结局指标
主要结局
safety data, including AEs, laboratory evaluations, ECG results, and vital signs assessments, will be listed by subject and summarized by dose and time point
时间窗: 28 days
次要结局
- Time to maximum plasma concentrations (tmax) will be summarized using descriptive statistics by visit and dose level(Day 1, 10 and 28)
- Maximum plasma concentration (Cmax) will be summarized using descriptive statistics by visit and dose level(Day 1, 10 and 28)
- Percent change from baseline in total PASI will be summarized using descriptive statistics by visit and dose level(28 days)
- Half life (t½) will be summarized using descriptive statistics by visit and dose level(Day 1, 10 and 28)
- The area under the plasma concentration versus time curve, from time 0 to the last measurable concentration (AUCt) will be summarized using descriptive statistics by visit and dose level(Day 1, 10 and 28)
- The area under the plasma concentration versus time curve, from time 0 to infinity (by extrapolation) (AUC∞) will be summarized using descriptive statistics by visit and dose level(Day 1, 10 and 28)
研究者
研究点 (14)
Loading locations...
相似试验
已完成
1 期
An Ascending Multiple Dose Study With VTP-43742 in Healthy VolunteersPsoriasisNCT03724292Vitae Pharmaceuticals Inc., an Allergan affiliate40
已完成
2 期
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT01397578Genentech, Inc.91
已完成
2 期
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)Alzheimer's DiseaseNCT01343966Genentech, Inc.448
已完成
1 期
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375Healthy VolunteersNCT05026008Shanghai SIMR Biotechnology Co., Ltd.72
已完成
2 期
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or IIHereditary AngioedemaNCT04208412KalVista Pharmaceuticals, Ltd.84